What it's for (Indications)
- Etanercept is a biological disease-modifying antirheumatic drug (DMARD) indicated for the treatment of various inflammatory and autoimmune conditions.
- In adults, it is approved for moderate to severe rheumatoid arthritis (RA) that has responded inadequately to one or more conventional disease-modifying antirheumatic drugs (DMARDs), including methotrexate.
- It is also indicated for the treatment of active psoriatic arthritis (PsA), a chronic inflammatory musculoskeletal condition, and for active ankylosing spondylitis (AS), a progressive inflammatory disease primarily affecting the spine.
- For dermatological conditions, etanercept is approved for chronic moderate to severe plaque psoriasis (Ps) in adult patients who are candidates for systemic therapy or phototherapy.
- In pediatric populations, etanercept is indicated for moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years and older, and for chronic moderate to severe plaque psoriasis in children aged 4 years and older who are candidates for systemic therapy or phototherapy.
- The decision to initiate etanercept therapy should be made after careful consideration of the potential benefits and risks associated with treatment, often in consultation with a specialist in rheumatology or dermatology.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for etanercept varies significantly depending on the specific indication, patient age, and body weight. For adult patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, the standard recommended dosage is 50 mg administered subcutaneously once weekly. Alternatively, for adult RA, a dosage of 25 mg administered subcutaneously twice weekly, with injections spaced 72-96 hours apart, can also be used. For adult patients with chronic moderate to severe plaque psoriasis, an initial dosage of 50 mg administered subcutaneously twice weekly is typically given for 12 weeks, followed by a maintenance dosage of 50 mg once weekly thereafter. Pediatric patients aged 4 years and older with chronic moderate to severe plaque psoriasis are dosed based on weight, typically 0.8 mg/kg (up to a maximum of 50 mg per dose) administered once weekly. For pediatric patients aged 2 years and older with moderately to severely active polyarticular juvenile idiopathic arthritis, the recommended dosage is 0.8 mg/kg (up to a maximum of 50 mg per dose) administered subcutaneously once weekly. All injections are administered subcutaneously. Patients or caregivers must receive thorough training on aseptic injection techniques, proper handling, and safe disposal of needles and syringes. Adherence to the prescribed dosing schedule is paramount for optimizing therapeutic outcomes and ensuring patient safety. |
Safety & Warnings
Common Side Effects
- Etanercept therapy is associated with a wide spectrum of potential side effects, ranging from mild and transient to severe and life-threatening, thereby necessitating vigilant patient monitoring.
- Common adverse reactions, reported in more than 10% of patients, frequently include injection site reactions such as erythema, pruritus, pain, or swelling, which are generally mild and self-limiting.
- Other commonly observed side effects involve upper respiratory tract infections, headache, and rhinitis.
- However, more serious adverse events, which require immediate medical attention, encompass severe infections such as bacterial sepsis, tuberculosis (including reactivation of latent TB), invasive fungal infections (e.
- g.
- , histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis), and other opportunistic pathogens.
- There is an increased risk of malignancy, including lymphoma and various solid organ cancers, particularly noted in children and adolescents.
- Cases of new-onset or exacerbation of central nervous system demyelinating disorders (e.
- g.
- , multiple sclerosis, optic neuritis, transverse myelitis) have been reported.
- Rare but severe hematologic reactions, including pancytopenia, aplastic anemia, and leukopenia, have occurred.
- Furthermore, new or worsening congestive heart failure and autoimmune reactions (e.
- g.
- , lupus-like syndrome, vasculitis) are potential concerns.
- Severe allergic reactions, including anaphylaxis and angioedema, are possible.
- Patients must be educated on recognizing and promptly reporting any unusual or severe symptoms to their healthcare provider.
Serious Warnings
- Black Box Warning: **WARNING: SERIOUS INFECTIONS AND MALIGNANCY** **SERIOUS INFECTIONS:** Patients treated with etanercept are at an increased risk for developing serious infections that may lead to hospitalization or death. These serious infections include: * **Active Tuberculosis (TB)**, including reactivation of latent TB. Patients should be thoroughly evaluated for TB risk factors and tested for latent infection prior to and periodically during etanercept therapy. Treatment of latent TB infection should be initiated and completed prior to etanercept use. * **Invasive Fungal Infections**, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. These infections may be disseminated and require hospitalization. Antigen and antibody testing for invasive fungal infections may not be reliable in TNF blocker-treated patients. * **Bacterial, Viral, and Other Opportunistic Infections**, including Legionella and Listeria. Close monitoring for signs and symptoms of infection, including TB, is essential in all patients receiving etanercept, even those who test negative for latent TB. Etanercept should be discontinued if a patient develops a serious infection. The risks and benefits of treatment should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection, or with underlying conditions that may predispose them to infection. **MALIGNANCY:** Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including etanercept. Postmarketing cases of leukemia, lymphomas, and solid organ malignancies have been reported in both adult and pediatric patients treated with TNF blockers. Given the risks, a careful assessment of the potential risks and benefits should be performed for each patient.
- Patients receiving etanercept are at a significantly increased risk of developing serious infections, which can lead to hospitalization or even death.
- These serious infections include tuberculosis (both active and latent forms), bacterial sepsis, invasive fungal infections (e.
- g.
- , histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis), and other opportunistic infections.
- Prior to initiating therapy, all patients must be comprehensively evaluated for active tuberculosis infection, risk factors for TB exposure, and latent infection.
- If latent TB is identified, appropriate treatment must be initiated and completed before starting etanercept.
- Continuous and careful monitoring for any signs or symptoms of infection, including tuberculosis, is critical throughout the entire course of etanercept treatment and beyond.
- Etanercept should be immediately discontinued if a patient develops a serious infection.
- Furthermore, there is an established increased risk of malignancy with TNF blockers, including lymphoma and other cancers, particularly observed in children and adolescents, and non-melanoma skin cancers in adults.
- New onset or worsening of pre-existing congestive heart failure has been reported in patients taking etanercept.
- Cases of central nervous system demyelinating disorders, such as multiple sclerosis, optic neuritis, and transverse myelitis, have been observed in patients treated with etanercept.
- Rare but severe hematologic adverse events, including pancytopenia, aplastic anemia, and leukopenia, have occurred; patients should be advised to seek immediate medical attention if they develop persistent fever, bruising, bleeding, or pallor.
- Reactivation of Hepatitis B virus has also been reported in chronic carriers.
- Live vaccines should not be administered concurrently with etanercept therapy due to potential risks.
- Concurrent use of etanercept with anakinra or abatacept is not recommended due to an increased risk of serious infections without additional demonstrated clinical benefit.
How it Works (Mechanism of Action)
Etanercept is a dimeric fusion protein that functions as a highly specific, soluble receptor for tumor necrosis factor (TNF). Its unique molecular structure consists of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) fused to the Fc portion of human immunoglobulin G1 (IgG1). This innovative design allows etanercept to act as a 'decoy receptor' that robustly and competitively binds to both soluble and transmembrane forms of TNF, thereby effectively preventing TNF from interacting with its native cell surface TNF receptors. TNF is a pivotal, naturally occurring pro-inflammatory cytokine that plays a central and critical role in orchestrating normal inflammatory and immune responses. However, in chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, TNF is found in excessive concentrations and is a key driver of inflammation, tissue damage, and disease progression. By efficiently sequestering and neutralizing both TNF-alpha and TNF-beta (lymphotoxin alpha), etanercept disrupts the TNF-mediated inflammatory cascade, leading to a significant reduction in inflammation, pain, and swelling, and potentially slowing the progression of structural damage in affected joints. The selective inhibition of TNF is fundamental to its therapeutic efficacy in these chronic autoimmune and inflammatory diseases.
Commercial Brands (Alternatives)
No other brands found for this formula.